SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

HSBCs bearish view on CoreWeave has amplified concerns about its debt-heavy data-center expansion, rising financing costs, and potentially slowing AI demand. Traders are split between buying the selloff and anticipating a short squeeze, and warning that credit and insider-selling risks could prolong the decline.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being tied by traders to weakening confidence in Trump and the approaching midterms, alongside concerns about the companys limited business fundamentals and Truth Social. The discussion is broadly bearish, though some traders view the decline as a possible short-term trading bounce.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound toward a one-year high and the $30 level is driving discussion, with traders focused on whether the move can break through resistance. Some see momentum from a defensive-sector rotation and pipeline developments ahead of earnings, while others say the stock needs stronger news to sustain a breakout.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp neocloud and AI-infrastructure selloff as traders weigh Gartners warning about the sectors economics and broader concerns over debt, funding, and project execution. The community is split between expecting further declines and buying an oversold dip; some cite the CEOs assurances about data-center financing, while others point to Horizon 2 delays and weak price action.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention for a sharp rebound after a tech-led selloff, which traders link to unconfirmed reports of potential U.S.-Iran talks and easing oil prices. The community is split between viewing the move as a bullish reversal and warning it may be a bull trap amid persistent volatility and concerns about tech and AI stocks.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp, extended semiconductor selloff has put SOXX in focus, with traders debating whether fears over AI spending returns, debt and crowded positioning signal a deeper downturn or an oversold bounce. Some see upcoming chip and hyperscaler earnings as a test of demand and capex, while others remain cautious about the sectors technical weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Should You Invest in the VanEck Biotech ETF (BBH)?

The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP

Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.

Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth 

 Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.

Healthcare ETFs Are Looking Up: Here's Why 

Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment 

Equity

 U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

VanEck ETF Trust - VanEck Biotech ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Chronic HDV is considered the most severe form of viral hepatitis.</li><li>Bulevirtide 2 mg is also approved for use in the European Economic Area (EEA).&nbsp;</li><li>Gilead Sciences concluded the acquisition of Germany -based biotech firm Tubulis.</li></ul>Gilead Sciences (<a href="https://stocktwits.com/symbol/GILD">GILD</a>) share price gained nearly 3% on Friday and was set to record its best day in about three months after Federal regulators granted accelerated approval to Hepcludex, making it the first and only approved treatment in the U.S. for adults with chronic hepatitis delta virus infection.&nbsp;Chronic hepatitis delta, or HDV, only occurs as a co-infection in individuals who already carry the hepatitis B virus. It is associated with rapid progression to liver disease, liver failure, liver cancer and death. Health officials estimate that the disease affects between 40,000 and 80,000 Americans."Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available," said Dr. Wendy Carter, acting director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research.Hepcludex, known chemically as bulevirtide-gmod, acts as a first-in-class entry inhibitor, blocking both HDV and hepatitis B from entering liver cells and disrupting the viral lifecycle. It is administered via a once-daily injection for adults who either do not have cirrhosis or have compensated cirrhosis, a state where the liver is scarred but still functional.&nbsp;"The approval of Hepcludex represents a historic milestone for people living with HDV in the United States," said Dr. Dietmar Berger, chief medical officer at Gilead Sciences in a statement. "This reflects years of close engagement with the FDA and the application of rigorous science to address a serious disease with long-standing unmet need."&nbsp;In the U.S., HDV affects between 2% and 4% of individuals who have chronic hepatitis B virus (HBV), representing ~40,000-80,000 people, Gilead said in a release citing studies.&nbsp;<h2 class="st-heading-2">MYR301 study&nbsp;</h2>The FDA’s decision was heavily informed by data from a multi-center Phase 3 clinical trial, known as MYR301.Participants were randomly assigned to immediate treatment with Hepcludex 8.5 mg once daily for 144 weeks or to delayed treatment with an observational period of 48 weeks followed by Hepcludex 8.5 mg once daily for 96 weeks.Furthermore, data showed that the percentage of participants with completely undetectable viral levels climbed steadily from 20% at week 48 to 50% by week 144.The FDA previously granted Hepcludex breakthrough therapy and orphan-drug designations to expedite its review. While newly approved in the U.S., a 2 mg dose of the drug has already been available in the European Economic Area and other global markets.&nbsp;<h2 class="st-heading-2">GILD Retail View&nbsp;</h2>Retail sentiment on Stocktwits was ‘normal’ with ‘high’ message volumes.&nbsp;The stock has gained 29% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Sciences (GILD) share price gained nearly 3% on Friday and was set to record its best day in about three months after Federal regulators granted accelerated approval to Hepcludex, making it the first and only approved treatment in the U.S. for adul

VanEck Biotech ETF

Gilead Sciences, Inc.

iShares Biotechnology ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Fundamentals

Info

BBH VanEck Biotech ETF

Fundamentals

Latest BBH News